CoChat

Research Priorities in Hypertrophic Cardiomyopathy: Report of a Working Group of the National Heart, Lung, and Blood Institute

Open access
Force, Thomas, Bonow, Robert O., Houser, Steven R., Solaro, R. John, Hershberger, Ray E., Adhikari, Bishow, Anderson, Mark E., Boineau, Robin, Byrne, Barry J., Cappola, Thomas P., Kalluri, Raghu, LeWinter, Martin M., Maron, Martin S., Molkentin, Jeffery D., Ommen, Steve R., Regnier, Michael, Tang, W. H. Wilson, Tian, Rong, Konstam, Marvin A., Maron, Barry J., Seidman, Christine E. · 2010 · Circulation
Cited by 120

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

ypertrophic cardiomyopathy (HCM) is a myocardial dis- order characterized by left ventricular (LV) hypertrophy without dilatation and without apparent cause (ie, it occurs in the absence of severe hypertension, aortic stenosis, or other cardiac or systemic diseases that might cause LV hypertrophy).Numerous excellent reviews and consensus documents provide a wealth of additional background.[1][2][3][4][5][6][7][8] HCM is the leading cause of sudden death in young people and leads to significant disability in survivors.It is caused by mutations in genes that encode components of the sarcomere.Cardiomyocyte and cardiac hypertrophy, myocyte disarray, interstitial and replacement fibrosis, and dysplastic intramyocardial arterioles characterize the pathology of HCM.Clinical manifestations include impaired diastolic function, heart failure, tachyarrhythmia (both atrial and ventricular), and sudden death.At present, there is a lack of understanding of how the mutations in genes encoding sarcomere proteins lead to the phenotypes described above.Current therapeutic approaches have focused on the prevention of sudden death, with implantable cardioverter defibrillator placement in high-risk patients.But medical therapies have largely focused on alleviating symptoms of the disease, not on altering its natural history.The present Working Group of the National Heart, Lung, and Blood Institute brought together clinical, translational, and basic scientists with the overarching goal of identifying novel strategies to prevent the phenotypic expression of disease.Herein, we identify research initiatives that we hope will lead to novel therapeutic approaches for patients with HCM. EpidemiologyThe epidemiology of HCM suggests that it is present in Ϸ1 in 500 adults.9 Because of the delay in phenotypic expression of the disease, HCM is not commonly recognized clinically in young children, but when it is, it is much more frequently recognized in males.10 This is likely due to greater penetrance in young males.11,12 HCM is underdiagnosed clinically in blacks and in women, yet women tend to present with more marked heart failure than men when they are diagnosed later in life.13,14 There is no overall difference in mortality, including sudden cardiac death, between men and women, although sudden cardiac death on the athletic field predominantly occurs in men.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.110.950089

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 120

Metadata

Authors
Force, T., Bonow, R. O., Houser, S. R., Solaro, R. J., Hershberger, R. E., Adhikari, B., Anderson, M. E., Boineau, R., Byrne, B. J., Cappola, T. P., Kalluri, R., LeWinter, M. M., Maron, M. S., Molkentin, J. D., Ommen, S. R., Regnier, M., Tang, W. H. W., Tian, R., Konstam, M. A., Maron, B. J., & Seidman, C. E.
Venue
Circulation
Published
2010-09-14
Volume
122
Issue
11
Pages
1130-1133
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2142387793
Cited by
120
References
2
FWCI
8.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.